PMID- 18705154
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20080818
LR  - 20191111
IS  - 1443-9506 (Print)
IS  - 1443-9506 (Linking)
VI  - 12
IP  - 3
DP  - 2003
TI  - Randomised double-blind, placebo-controlled trial of coenzyme Q, therapy in class 
      II and III systolic heart failure.
PG  - 135-41
AB  - BACKGROUND: Coenzyme Q10 (CoQ10) supplementation has been reported to improve 
      symptoms of heart failure and quality of life, and to reduce hospitalisation. 
      Most prior trials have been open-label and in some, only 50% of patients took 
      angiotensin converting enzyme inhibitors (ACEI). AIM: To determine the effects of 
      CoQ10 in patients with a New York Heart Association (NYHA) Class II or III heart 
      failure due to ischaemic or dilated cardiomyopathy who have been treated with 
      ACEI but not beta-blockers. METHODS: Thirty-nine patients in NYHA Class II or III 
      heart failure were randomised in ad ouble-blind, placebo-controlled study with 
      150 mg/day of oral CoQ10 or placebo. RESULTS: Thirty-five patients completed the 
      trial. After 3 months of therapy, the NYHA class in the CoQ10 group (n = 17) 
      showed a significant improvement of 0.5 class compared with the placebo (n = 18) 
      (P = 0.01). Specific Activities Scale class showed a significant (P = 0.004) 
      improvement in the CoQ10 group, but no change in the placebo group. The C-min 
      walk-test distance showed a significant (P = 0.047) increase in the CoQ10 group 
      with no change in the placebo group (between-group difference P = 0.29). For the 
      Naughton exercise test times the difference in increase in exercise time 
      approached significance in favour of the CoQ10 group (P = 0.056). There was a 
      correlation between the increase in exercise time and the increase in serum CoQ10 
      level (P = 0.024). There was a threefold increase in the CoQ10 level in the 
      treated group (0.7 +/- 0.4 to 2.1+/- 0.3 microg/mL), but no change in the placebo 
      group. CONCLUSIONS: This pilot study accords with published data suggesting that 
      CoQ10 therapy improves cardiac functional status in patients with moderately 
      severe dilated cardiomyopathy receiving maximal non beta-blocker therapy. Future 
      multicentre studies with larger numbers are indicated.
FAU - Keogh, Anne
AU  - Keogh A
AD  - Heart Failure Unit, St Vincent's Hospital, Sydney, Australia.
FAU - Fenton, Steve
AU  - Fenton S
FAU - Leslie, Christina
AU  - Leslie C
FAU - Aboyoun, Christina
AU  - Aboyoun C
FAU - Macdonald, Peter
AU  - Macdonald P
FAU - Zhao, Yi Chen
AU  - Zhao YC
FAU - Bailey, Michael
AU  - Bailey M
FAU - Rosenfeldt, Franklin
AU  - Rosenfeldt F
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Heart Lung Circ
JT  - Heart, lung & circulation
JID - 100963739
EDAT- 2008/08/19 09:00
MHDA- 2008/08/19 09:01
CRDT- 2008/08/19 09:00
PHST- 2008/08/19 09:00 [pubmed]
PHST- 2008/08/19 09:01 [medline]
PHST- 2008/08/19 09:00 [entrez]
AID - S1443-9506(03)90062-X [pii]
AID - 10.1046/j.1443-9506.2003.00189.x [doi]
PST - ppublish
SO  - Heart Lung Circ. 2003;12(3):135-41. doi: 10.1046/j.1443-9506.2003.00189.x.